NASDAQ:TRAW
Traws Pharma, Inc.
Traws Pharma, Inc.'s revenue grew 1134.5% in fiscal 2025 to $2.8M while operating margin rose to −640.7%. Free cash flow was −$20.8M, −744.4% of revenue, and the diluted share count rose 439.5%.Summary generated from Traws Pharma, Inc.'s SEC filings. Latest annual report filed Apr 15, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.8M
Revenue growth+1134.5%
Revenue, 5-yr CAGR+64.6%
Gross marginn/a
Operating margin−640.7%
Net margin328.7%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$20.8M
FCF margin−744.4%
Share count change+439.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 3 |
| Operating income | −16 | −20 | −20 | −142 | −18 |
| Net income | −16 | −19 | −19 | −167 | 9 |
| Free cash flow | n/a | n/a | −18 | −33 | −21 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026 - 8-KNotice of delisting or listing-rule failure
Jul 31, 2026 - 4Insider transaction report
Jul 16, 2026 - 4Insider transaction report
Jul 15, 2026 - 8-KOther events
Jul 10, 2026 - 8-KDirector or officer change
Jul 9, 2026 - 8-KRegulation FD disclosure
Jun 22, 2026